| NCT06245291 | Study of Imdusiran (AB-729) in Combination With Intermittent Dosing of Durvalumab in Subjects With Chronic HBV Infection | WITHDRAWN | PHASE2 | 2024-05-01 | 2024-08-01 | 2024-08-01 |
| NCT05960240 | Safety, Tolerability, PK & PD of AB-101 Following Oral Administration in Healthy and CHB Subjects. | ACTIVE_NOT_RECRUITING | PHASE1 | 2023-08-30 | 2026-04 | 2026-01 |
| NCT04980482 | Open-Label Study of AB-729, Nucleos(t)Ide Analogue and Pegylated Interferon Alfa-2a in Subjects With Chronic Hepatitis B Infection | ACTIVE_NOT_RECRUITING | PHASE2 | 2021-10-29 | 2025-06 | 2025-03-13 |
| NCT04775797 | Safety, Tolerability, and Pharmacokinetics of AB-836 in Healthy Subjects and Subjects With Chronic HBV Infection | TERMINATED | PHASE1 | 2021-06-25 | 2022-11-17 | 2022-11-17 |
| NCT02631096 | Study of ARB-001467 in Subjects With Chronic HBV Infection Receiving Nucleos(t)Ide Analogue Therapy | COMPLETED | PHASE2 | 2015-12 | 2018-05-18 | 2018-05-18 |
| NCT02191878 | Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Intravenous TKM-080301 in Subjects With Advanced Hepatocellular Carcinoma | COMPLETED | PHASE1, PHASE2 | 2014-06 | 2016-07 | 2016-05 |
| NCT02041715 | Safety, Tolerability and Pharmacokinetic First in Human (FIH) Study for Intravenous (IV) TKM-100802 | TERMINATED | PHASE1 | 2014-01 | 2015-07 | 2015-07 |
| NCT01518881 | Safety, Tolerability and Pharmacokinetic First in Human (FIH) Study of Intravenous (IV) TKM-100201 Infusion | TERMINATED | PHASE1 | 2012-01 | 2012-07 | 2012-07 |
| NCT01262235 | A Dose Finding Study of TKM-080301 Infusion in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients | COMPLETED | PHASE1, PHASE2 | 2010-12 | 2015-08 | 2015-07 |
| NCT00927459 | Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Liposomal siRNA in Subjects With High Cholesterol | TERMINATED | PHASE1 | 2009-06 | 2010-01 | 2009-12 |